The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy

Vasim Farooq¹, MBChB, MRCP; Chrysaftis Girasis¹, MD; Michael Magro¹, MD; Yoshinobu Onuma¹, MD; Marie-Angèle Moréf², BSc; Jung Ho Heo¹, MD; Hector M. Garcia-García², MD; Arie Pieter Kappetein³, MD, PhD; Marcel van den Brand², MD; David R. Holmes⁴, MD; Michael Mack³, MD; Ted Feldman⁶, MD; Antonio Colombo⁷, MD; Elisabeth Stähle⁵, MD; Stefan James⁸, MD; Didier Carrié⁹, MD; Gerard Fournial⁹, MD; Gerrit Anne van Es², PhD; Keith D. Dawkins¹⁰, MD; Friedrich W. Mohr¹¹, MD; Marie-Claude Morice¹², MD; Patrick W. Serruys¹*, MD, PhD

1. Department of Interventional Cardiology, Erasmus University Medical Centre, Thoraxcenter, Rotterdam, The Netherlands; 2. Cardialysis BV, Rotterdam, The Netherlands; 3. Department of Cardiothoracic Surgery, Erasmus University Medical Centre, Thoraxcenter, Rotterdam, The Netherlands; 4. The Mayo Clinic, Rochester, MN, USA; 5. Medical City Dallas Hospital, Dallas, TX, USA; 6. Evanston Hospital, Evanston, IL, USA; 7. San Raffaele Scientific Institute, Milan, Italy; 8. University Hospital Uppsala, Uppsala, Sweden; 9. Centre Hôpital Universitaire Rangueil, Toulouse, France; 10. Boston Scientific Corporation, Natick, MA, USA; 11. Herzzentrum, Leipzig, Germany; 12. Institut Jacques Cartier, Massy, France

We recently reported the coronary artery bypass graft (CABG) SYNTAX Score, an objective measure of anatomical complexity and revascularisation post coronary artery bypass graft (CABG) surgery¹. At four-year follow-up, a non-significant trend towards more adverse clinical outcomes, including all-cause death, was reported in the higher CABG SYNTAX group (≥22)¹. The final five-year outcomes of the SYNTAX trial have recently been reported²³. We report the five-year outcomes of the CABG SYNTAX Score from the CABG arm of the SYNTAX-LE MANS left main angiographic substudy.

At five years, significantly greater all-cause death was seen in the high CABG SYNTAX Score group (≥22) compared to the low CABG SYNTAX Score group (<22) (14.5% vs. 9.1%, log rank p-value=0.012) (Figure 1). Similarly, significantly greater five-year all-cause death/cerebrovascular accident (CVA)/myocardial infarction (MI) (log rank p-value=0.025) and MACCE (major adverse cardiac and cerebrovascular events) (log rank p-value=0.050) were reported.

Incomplete revascularisation (ICR) has recently been hypothesised and shown to be a surrogate marker of a greater burden and complexity of coronary disease, other vascular disease, and clinical comorbidity, in both CABG and PCI (percutaneous coronary intervention) treated patients⁴. Specifically, in the all-comers CABG and PCI arms of the SYNTAX trial, adverse long-term (four-year) clinical outcomes – including mortality, all-cause revascularisation, and MACCE – were shown to occur more frequently in patients who were incompletely revascularised.

The CABG SYNTAX Score and its PCI equivalent, the residual SYNTAX Score⁶, both provide objective measures of the complexity of the residual disease and level of revascularisation. These scores may aid in determining a level of “reasonable revascularisation” after undergoing surgical or percutaneous-based revascularisation⁷, and may have a long-term prognostic role in identifying high-risk patients undergoing CABG or PCI. Validation studies are awaited.

*Corresponding author: Department of Interventional Cardiology, Erasmus MC, ’s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl

© Europa Digital & Publishing 2013. All rights reserved.
Acknowledgements
The authors would like to thank all the study centres and participants.

Funding
The SYNTAX trial was funded by Boston Scientific.

Conflict of interest statement
K. Dawkins is a full-time employee of, and holds stock in, Boston Scientific. M. Mack has served on the speakers bureau of Boston Scientific, Cordis and Medtronic. T. Feldman has served on the speakers bureau of Abbott, Atritech, Boston Scientific Corporation, Edwards, and Evalve; and has worked as a consultant for Abbott, Coherex, Intervalve, Square One, and WL Gore. M-A. Morel’s institution has received a research grant from Boston Scientific. M-A. Morel, H.M. Garcia-Garcia and G.A. van Es are employees of Cardialysis. The other authors have no conflicts of interest to declare.

References


